Compugen Ltd (NAS:CGEN)
$ 1.57 -0.06 (-3.68%) Market Cap: 141.45 Mil Enterprise Value: 31.69 Mil PE Ratio: 52.62 PB Ratio: 2.33 GF Score: 53/100

Compugen Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 01:30PM GMT
Release Date Price: $17.88 (+3.65%)
Unidentified Analyst

Good morning, everybody. It's Albert Wong from Morgan Stanley. Welcome to the third day of our Virtual Health Care Conference. I have with us Compugen, very exciting company based in Israel.

I will hand it off to Anat, the CEO; and Ari, the CFO, who can introduce the rest of the team. And we will go through a presentation for a few minutes and then open it up to Q&A. Anat?

Anat Cohen;Dayag
Compugen Ltd. - CEO, President & Director

Thank you, Albert, and thank you for Morgan Stanley to invite us to the conference. Today, with me today, as Albert was saying, Ari Krashin, the CFO of the company. But also Dr. Henry Adewoye, the CMO of the company; and Dr. Eran Ophir, which is heading the research and drug discovery at Compugen. And I'll start with a brief overview we'll go to the Q&A.

You can look at Slide #3. Compugen is a therapeutic discovery and development company. We discover new drug targets, and we developed first-in-class drugs to address these drug targets. We're focusing the field of cancer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot